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Abstract 
 
Background  
Associations between antimicrobial exposure in the community and community-associated 
Clostridioides difficile infection (CA-CDI) are well documented but associations with 
healthcare-associated CDI (HA-CDI) are less clear. This study estimates the association 
between antimicrobial prescribing in the community and HA-CDI. 
Methods 
A matched case-control study was conducted by linking three national patient level datasets 
covering CDI cases, community prescriptions and hospitalisations. All validated cases of HA-
CDI (August 2010 - July 2013) were extracted and up to three hospital-based controls were 
matched to each case on the basis of gender, age, hospital and date of admission. Conditional 
logistic regression was applied to estimate the association between antimicrobial prescribing 
in the community and HA-CDI. We conducted sensitivity analysis to consider the impact of 
unmeasured hospital antimicrobial prescribing. 
Results 
930 unique cases of HA-CDI with onset in hospital and no hospital discharge in the 12 weeks 
prior to index admission were linked with 1810 matched controls. Individuals with prior 
prescription of any antimicrobial in the community had an odds ratio (OR) = 1.40 (95% CI 1.13-
1.73) for HA-CDI compared to those without. Individuals exposed to high risk antimicrobials 
(cephalosporins, clindamycin, co-amoxiclav, or fluoroquinolones) had an OR=1.83 (95% CI: 
1.31-2.56). After accounting for the likely impact of unmeasured hospital prescribing, the 
community exposure, particular to high risk antimicrobials, was still associated with elevated 
HA-CDI risk. 
Conclusions 
Community antimicrobial exposure is an independent risk factor for HA-CDI and should be 
considered as part of the risk assessment of patients developing diarrhoea in hospital.   
Introduction 
 
Clostridioides difficile infection (CDI) is a global challenge1,2 and a major public health problem 
in both healthcare and community settings. In Scotland, the annual incidence of healthcare-
associated CDI (HA-CDI) in 2016 was 15.4 per 100 000 total bed days compared to 7.5 per 100 
000 population for community-associated CDI (CA-CDI)3. Although a reduction in HA-CDI in 
Scotland has been observed over time, 58% of all cases were HA-CDI in 2016. 
Antimicrobial exposure is a significant risk factor for CDI that is potentially modifiable. 
Associations between community antimicrobial exposure and CA-CDI are clearly 
demonstrated4-7, but any residual impact on the risk of HA-CDI is challenging to differentiate 
from the impact of antimicrobial exposure in the healthcare setting. A recent systematic 
review, found that overall exposure to antimicrobials was associated with a 60% (95% CI 30%-
90%) increased risk of HA-CDI however the included studies either only looked at hospital 
prescribing or did not differentiate between community and hospital prescribing8. No studies 
examined the residual effect of community prescribing on the risk of HA-CDI, and there were 
limited large studies to enable accurate quantification of the risk of antimicrobial prescribing 
on HA-CDI8.  
This study included all HA-CDI cases in Scotland (population of ~5.3 million) enabled through 
our national Infection Intelligence Platform (IIP) which synergizes the wealth of infection-
related health data to provide timely and efficient analysis of our antimicrobial stewardship 
programs10. 
The aims of this study are to estimate the association between antimicrobial prescribing in 
the community and the development of HA-CDI considering exposure to, (i) any antimicrobial 
and (ii) specific broad spectrum antimicrobials, whilst accounting for the unmeasured 
confounder of hospital antimicrobial prescribing. The effect of cumulative antimicrobial 
exposure on the risk of HA-CDI and the temporal relationship between timing of antimicrobial 
exposure and risk of HA-CDI are also examined. 
  
Population and methods 
 
Data Linkage & Case-Control Assignment 
 
A matched case control study was conducted by linking three national patient level datasets: 
ECOSS (Electronic Communication of Surveillance in Scotland – positive microbiology 
laboratory specimens for key infections); SMR01 (Scottish Morbidity Record– the General / 
Acute and Inpatient Day Case dataset recording hospital discharges); PIS (Prescribing 
Information System – prescriptions dispensed in the community)10. The completeness for 
SMR01 extract is around 99%11 and for PIS extract is over 87%12. Due to mandatory 
surveillance for CDI in Scotland13, our data should capture all CDI cases. The datasets were 
linked using the unique patient identifier, the community health index (CHI), used across all 
health service contacts in Scotland.  
 
All validated CDI cases with a date of testing between August 2010 (to allow 1 year of look 
back of community prescriptions on PIS) and July 2013 (most recent validated CDI case data 
available at time of data extraction) were extracted from ECOSS.  All diarrhoeal samples are 
tested using a 2-step diagnostic algorithm: first step, - screen for the presence of C. difficile 
glutamate dehydrogenase antigen; second step, test for the presence of toxin A/B in enzyme 
immunoassay (only samples positive in both steps are reported as positive). Positive tests 
were then validated by the NHS board against local laboratory and patient records to confirm 
all clinically symptomatic CDI episodes and entered into ECOSS.   
 
Cases were linked to hospitalisation history from SMR01 for case classification. Cases were 
categorised as HA-CDI if the date of positive test was on day three or later of a hospital 
admission and/or within four weeks of a previous hospital discharge14. For this study, only 
hospital-onset HA-CDI (HO HA-CDI) cases were included, cases with hospital discharge in the 
12 weeks prior to index admission were excluded to minimise the impact of unmeasured risk 
factors in previous admissions.  For cases with multiple episodes of HA-CDI, one episode was 
chosen randomly for inclusion. 
 
Up to three hospital based controls were matched to cases on the basis of age (within 5 years), 
gender, hospital and admission date (within 7 days, and in hospital on the case’s CDI test 
date). Controls were excluded if they had hospitalisation in the 12 weeks prior to the current 
admission.  
 
Individual community prescription records from August 2009 onwards and five years of 
hospitalisation records prior to the CDI date were linked to cases and controls using CHI. Two 
antimicrobial exposure categories in the six months prior to CDI test date were considered; 
any antimicrobial (only antibacterials not antiviruals or antifungals; Leprosy and TB are very 
different to most other antibacterials and not implicated in CDI so excluded) and, separately, 
a higher risk group (clindamycin, cephalosporins, fluoroquinolones and co-amoxiclav – 
referred to as “4C” antimicrobials). This group of broad-spectrum antibiotics have been 
shown to have a higher risk of contributing to CDI4,6,8,9. Detailed prescribing directions were 
not available but strength and volume information allowed calculation of each prescription 
and cumulative exposure as WHO defined daily doses (DDDs)15. DDD is the average 
maintenance dose per day for a drug used for its main indication in adults15. 
 
Risk factors considered were: hospital admission (yes/no) in the year prior to CDI;  burden of 
co-morbidities derived from prescribing - number of total prescriptions (all drugs) and 
number of different prescriptions (based on approved name) dispensed in the year prior to 
CDI16 and the Charlson Index - based on International Classification of Diseases 10 (ICD 10) 
discharge codes from all hospital admissions in the 5 years prior to CDI17-19; speciality for the 
index admission; care home residency (yes/no); Scottish Index of Multiple Deprivation (SIMD) 
quintile20 from CHI Registry; length of inpatient stay before infection (days from index 
admission until CDI test date – each control used the pseudo CDI test date from the matched 
case); proton pump inhibitor (PPI) and H2 antagonist exposure (present/absent) in the six 
months prior to CDI. 
 
 
Analysis  
The association between community antimicrobial exposure and HA-CDI was assessed using 
conditional logistic regression with all other risk factors adjusted for. The residual effect of 
community antimicrobial exposure might be stronger in those hospitalised for a shorter 
period of time therefore interaction tests were used to investigate if the effect was the same 
in those hospitalised for under or over seven days prior to CDI.  
 
For sensitivity analyses, we modelled how the unknown hospital prescribing of antimicrobials 
during the index CDI admission may influence the estimates21. The method specifies the likely 
proportion of unknown hospital antimicrobial prescribing in those exposed and unexposed to 
antimicrobials in the community along with the estimate of effect size of hospital prescribing 
on HA-CDI from the systematic review 8. We assumed three potential values for the increased 
odds of HA-CDI associated with hospital antimicrobial prescription, OR=1.6, 1.3 and 1.9 (point 
estimate and confidence boundaries) and more extreme scenarios of OR= 4 and 6. One third 
of hospital inpatients are on antimicrobials at any time22 and we assumed that those with a 
community antimicrobial prescription were more likely to have a hospital antimicrobial 
prescription, so we considered imbalances in the proportions with hospital prescribing from 
35%/31% to 47%/19% in those with/without community prescribing, respectively. 
Uncertainty around the antimicrobial prevalence among hospital inpatients and its impact on 
the results was also investigated – we changed the overall prevalence from assumed 33% to 
25%, 50% and 75% and reran the analysis. All analysis was conducted using R version 3.2.1.  
Results 
 
In total there were 3727 HA-CDI episodes in the time frame, of which 1235 (33.1%) were 
hospital onset and had no hospitalisation in the prior 12 weeks (Figure 1).  Matched controls 
(1867) were obtained for 961 cases and after randomly selecting one episode from those with 
multiple episodes, 930 cases and 1810 matched controls were identified.  
 
The study population was 59% female with median age 79 years (Table I). The average days 
of current hospitalisation before the matched date of CDI is longer for cases compared to 
controls (17 vs. 14 days). The cases were more likely than controls to have at least 1 prior 
hospital admission in previous year (44.4% vs. 39.1 %) but less likely to be resident in a care 
home (19.1% vs. 23.7%). The adjusted model showed that, there was increased risk of HA-CDI 
associated with comorbidity (Charlson score 4+ vs. 0 OR=2.72 95% CI: 1.63-4.53), higher 
numbers of drugs dispensed in the previous year (for unit increase OR=1.01 95% CI: 1.01-1.02 
for each additional drug), a longer duration of hospitalisation prior to infection (OR=1.11 95% 
CI: 1.08-1.15 for each additional day), previous hospital admissions (yes vs. no OR=1.30 95% 
CI: 1.04-1.63), no care home residency (yes vs.no OR=0.65 95% CI: 0.50-0.83) (Table I).  
 
Compared to the controls, a higher proportion of cases received any antimicrobial (42.6% 
vs.39.6%) and 4C group (13.0% vs. 9.6%) in the community in the previous 6 months. After 
adjusting for all other variables, prior antimicrobial exposure vs. no exposure in the 
community was associated with 40% increased odds of HA-CDI (OR 1.41 95% CI: 1.13 -1.75) 
(Table 1).  The OR was higher for exposure to 4Cs (OR=1.86 95% CI: 1.33-2.59). 
 
The effect of community 4C exposure was stronger in those hospitalised for less than one 
week prior to CDI diagnosis (Interaction test: p=0.02). For patients hospitalised for less than 
one week the OR for community 4C exposure vs. no exposure was 2.43 (95% CI: 0.998, 5.94) 
(Table II). 
 
The scale of the dose response relationship between prior exposure to any antimicrobial in 
the community and development of HA-CDI was not found to be particularly large (1-7 DDDs 
exposure adjusted OR=1.31 95% CI: 0.95-1.79; 29+ DDDs OR=1.90 95% CI: 1.31-2.74) although 
the p value for the linear trend test was significant (p=0.0006).  A similar result was found for 
dose response of prior 4C exposure was - compared to no exposure (Table III).  
 
A slight decreasing trend can be observed in the risk of developing CDI with time since any 
antimicrobial exposure, adjusted OR for <=30 days post exposure was 2.17 (95% CI: 1.53 - 
3.07) and decreasing to 1.75 (95% CI: 1.27-2.41) for 31-90 days post exposure and 0.97 (95% 
CI: 0.74-1.28) for 91 or more days, but the trend was not statistically significant (linear trend 
test p=0.5) (Table IV). The effect of 4C exposure was strongest within 90 days with little 
difference between the first month and those subsequent (OR <=30 days, 2.24 (95% CI: 1.32 
-3.78) and OR 31-90 days, 2.47 (95% CI: 1.42-4.32)). The association did not persist after 90 
days post exposure (OR 1.27 95% CI: 0.76-2.12). 
 
The potential impact of unknown hospital antimicrobial prescribing on the association 
between community antimicrobial prescription and HA-CDI was examined, with reasonably 
assumed parameters for unknown hospital prescribing (ORs for hospital prescribing to 
develop HA-CDI, prevalence of hospital prescribing in those with community exposure (p1) 
and without (p0)), Table V. With the increase in odds of HA-CDI associated with hospital 
antimicrobial exposure set at OR=1.6 the effect of any community antimicrobial exposure lost 
statistical significance at an imbalance in hospital exposure, between p0 and p1, of 19% versus 
47% (OR =1.22 95% CI: 0.98-1.52). However community 4C exposure remained significantly 
associated with increased odds of HA-CDI at this imbalance (OR =1.61 95% CI: 1.15-2.25). If 
the OR for hospital prescribing is increased to 6, the effect of any antimicrobial prescribing in 
the community became insignificant at imbalance of p0 = 29% to p1=37% while the effect of 
4C became insignificant at a larger imbalance of p0=25% to p1=41%. The results in Table V 
assumed that the overall prevalence of hospital prescribing was 33%. The impact of the 
variation of this overall prevalence to the results was investigated in Table A1. When the OR 
for hospital prescribing is low (OR=1.3) increasing the overall prevalence of hospital 
prescribing had little impact (up to 75%) on the measured association between HA-CDI and 
community prescribing. With a higher association (OR=6) a difference of difference between 
p0 and p1 of 4%, still showed significant associations even with a prevalence of hospital 
prescribing at 75%, however if the differential was greater (14%, 28%) then the association 
became reduced and the estimated odds became insignificant.   
Discussion 
 
Summary main findings 
This study examined the residual effect of antimicrobial prescribing in the community on the 
risk of HA-CDI. Prior antimicrobial exposure vs. no exposure in the previous 6 months in 
community was associated with 40% increased odds of HA-CDI, rising to 80% after exposure 
to a higher risk antimicrobials group. After accounting for unmeasured hospital antimicrobial 
exposure, community exposure, particularly to high risk antimicrobials, still appeared to 
influence the risk of HA-CDI. 
Strengths and limitations 
The 2014 review paper8 summarized the results on associations between prior antimicrobial 
exposure and the risk of HA-CDI. However, no studies examined community prescribing alone 
- three studies measured exposure during admission only whilst 10 studies measured 
antimicrobials received prior to and during admission combined. More recent work by 
Khanafer et al23 also only explored hospital prescribing. This study examined the independent 
risk of community prescribing on developing HA-CDI, not explored previously to our 
knowledge.   Additionally, most previous studies examined antimicrobial exposure in the prior 
4-6 week while our study included exposure up to 6 months before infection.   
Furthermore, our study is also at scale, second largest only to the USA Kaiser study24, the 
remaining studies in the review comprising mainly of one hospital site with two studies 
covering 9-12 hospital sites (n=317 and n=237).  In contrast, our study covered a national 
health system with data from 40 hospitals.  
A limitation of our study was the unmeasured confounder of hospital prescribing. To minimise 
this impact, we excluded cases with a hospitalisation in the preceding 12 weeks. Sensitivity 
analysis, using an approach demonstrated in other clinical studies25-26, was applied.  Our study 
showed the impact of community prescribing on HA-CDI reduced when the likely impact of 
hospital prescribing8 was accounted for but generally remained significant.  
All our HA-CDI cases were defined according to the clinical definition14 however cut-offs in 
the definition are in fact relatively arbitrary and there is much more of a continuum between 
the community and hospitals in terms of exposures, i.e. antimicrobials, and risk of infection 
transmission. Cases are attributed based on symptoms/sampling rather than when/where the 
bacteria was initially acquired (because it is common to have a period of asymptomatic 
carriage) so it is possible that some cases are misclassified in terms of acquisition source. 
A proportion of PPI/H2 antagonist consumption is likely attributable to over the counter use, 
which we cannot measure in this study and we are therefore likely to be  underestimating 
exposure to PPI/H2 antagonists which could modify the associations found if there is an 
imbalance in over the counter use between cases and controls.  
Data subsequently recorded since the time of the study (2013-2017), shows a decreasing year 
on year trend of 6.8% in the incidence rate of CDI in Scotland and a contemporaneous 
decrease of 10.8% in 4C prescribing in the community27, in line with antimicrobial stewardship 
policies. Given that our data predate this period, it is possible that changes in prescribing 
behaviour may have modified the relationships observed although the ecological pattern of 
a decrease in CDI with reductions in community prescribing, is consistent with the 
associations found in this study and in our previous work on community associated CDI7.  
Future work will seek to use an updated data extract and examine the impact of the change 
in prescribing on the associations found.  
Comparison with other work 
The review paper8 estimated ORs for different classes of antimicrobials (penicillins, 
clindamycin, trimethoprim, cephalosporins, carbapenems and fluoroquinolones; combined 
prior hospital and community prescribing) for risk of HA-CDI ranging from 1.45 (95% CI: 1.05-
2.02) for penicillin to 3.2 for third-generation cephalosporins (95% CI: 1.8-5.71) which was 
generally higher than our estimations for community prescribing to any antimicrobial 
(OR=1.41 95% CI: 1.13-1.75) and 4C (OR = 1.86 95% CI: 1.33-2.59). The differences are 
expected as our study estimated the residual risk from community prescribing whilst the 
other studies mainly quantified the risk of mixed hospital and community prescribing. 
Another potential contributory factor to the difference may be the variation in definition of 
HA-CDI within the review which led to high heterogeneity in the estimated pooled risk 
(ranging from >48 hours to >72 hours with one study >5 days and variation in hospitalisation 
prior to the index admission). 
Cumulative total exposure to any antimicrobial has been demonstrated to increase HA-CDI 
risk5,25,29 but community prescribing was not investigated alone in these studies. We found a 
lower effect of cumulative community exposure (OR=1.90 95% CI: 1.31-2.74 for >29 DDDs, 6 
months prior to CDI) compared to Hensgens et al who reported OR=8.5 95% CI: 4.6-15.9 for 
>=14 DDDs any antimicrobial use in both community and hospital in the 3 month prior to CDI, 
the difference most likely attributable to hospital prescribing. Further investigation of the 
cumulative exposure to the 4C subgroup is required due to small numbers in all studies to 
date.  
In our study, community exposure to PPI and H2 antagonist was not associated with an 
increased risk of HA-CDI – similar to23 where hospital exposure to PPI/H2 was examined with 
adjustment of prior antimicrobial use.  However, the impact of PPI/H2 on CDI remains 
uncertain with  Aseeri et al30 showing a significant increased CDI risk for inpatients with 
combined community and hospital PPI exposure (OR=3.08 95% CI: 1.61-5.91) when the cases 
and controls were matched on type, amount and duration of prior antimicrobial exposure.   
 
Finally, previous studies report care home residents as having higher risk of CDI6-7, due to 
increasing age, comorbidity, likelihood for infection transmission and antimicrobial 
exposure31. However, care home residents appeared to be at lower risk of HA-CDI in our study 
(adjusted OR=0.65 95% CI: 0.50-0.83). This is likely due to the selection of controls, matched 
on age, gender and length of admission before CDI diagnosis date, resulting in a relatively high 
proportion of care home residents (23.7% vs. 19.1% of cases). 
 
Conclusions 
 
It appears that community prescribing has an impact on risk of hospital onset HA-CDI.  
Additionally, the study has shown that the impact on risk of HO HA-CDI from antimicrobial 
exposure in the community can persist for up to 6 months, not reported before8,23.  
 
This evidence underpins our national strategy to continue to strive for a reduction in broad 
spectrum antibiotics, now evidenced by a decline in CDI rates and 4C prescribing31. Our 
findings also raise the awareness of the persistence of community exposure on risk during 
hospital stay, noteworthy for the risk assessment and management of patients developing 
diarrhoea both in Scotland and globally.   
 
Our study has used large scale data analytics to identify and quantify risk association 
retrospectively. The next phase is to link national data prospectively to inform new clinical 
decision tools using individual characteristics to derive personalised risk profiles to shape 
therapeutic management plans in the clinical setting.  
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Figure captions 
 
Figure 1: Flow chart of the episode selection and control assignment.  HA – Healthcare 
associated; HO – Hospital Onset; CO – Community Onset. 
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Table I:  Demographics, univariate and multivariate odds ratios of prior antimicrobial exposure and potential confounding variables for 6 
Healthcare associated CDI cases (HA-CDI) vs. hospital based controls. 7 
 8 
  Cases (n=930) 
n(%); 
Controls 
(n=1810) n(%); 
Unadjusted Adjusted (Any) Adjusted (4C) 
  median (IQR)a median (IQR)a OR (95% CI) OR (95% CI) OR (95% CI) 
No exposure to antibiotics in the previous 6 months 534 (57.4) 1093 (60.4) 1 1 1 
Exposed to antibiotics in the previous 6 months 396 (42.6) 717 (39.6) 1.22 (1.02, 1.45) 1.41 (1.13, 1.75) - 
Exposed to non-4C in the previous 6 months 275 (29.6) 544 (30.1) 1.11(0.92, 1.36) - 1.86 (1.33, 2.59) 
Exposed to 4C in the previous 6 months 121 (13.0) 173 (9.6) 1.50 (1.15, 1.97) - 1.29 (1.02, 1.63) 
Age 79 (70-86) 80 (72-86) - - - 
Female 536 (57.6) 1086 (60.0) - - - 
SIMD 1: most deprived 237 (25.6) 445 (24.7) 1 1 1 
SIMD 2 223 (24.1) 386 (21.4) 1.07 (0.82, 1.39) 1.06 (0.79, 1.42) 1.05 (0.78, 1.41) 
SIMD 3 159 (17.2) 348 (19.3) 0.82 (0.62, 1.10) 0.81 (0.60, 1.11) 0.81 (0.59, 1.11) 
SIMD 4 156 (16.9) 324 (18.0) 0.86 (0.65, 1.15) 0.94 (0.68, 1.29) 0.94 (0.68, 1.29) 
SIMD 5: least deprived 150 (16.2) 297 (16.5) 0.97 (0.72, 1.31) 1.08 (0.77, 1.52) 1.07 (0.76, 1.51) 
Unknown 5 10 - - - 
Charlson score 0 375 (40.3) 775 (42.8) 1 1 1 
Charlson score 1 156(16.8) 266 (14.7) 1.32 (1.02, 1.72) 1.20 (0.90, 1.61) 1.21 (0.90, 1.62) 
Charlson score 2 110 (11.8) 210 (11.6) 1.15 (0.86, 1.54) 1.18 (0.86, 1.63) 1.16 (0.84, 1.6)0 
Charlson score 3 52 (5.6) 81 (4.5) 1.46 (0.98, 2.17) 1.28 (0.82, 2.01) 1.28 (0.82, 2.01) 
Charlson score 4+ 46 (5.0) 50 (2.8) 2.25 (1.42, 3.55) 2.72 (1.63, 4.53) 2.71 (1.62, 4.52) 
Charlson score Unknownb 191 (20.5) 428 (23.7) 0.93 (0.74, 1.18) 1.06 (0.79, 1.41) 1.05 (0.79, 1.41) 
Admission speciality: general medicine 467 (50.2) 921 (50.9) 1 1 1 
Admission speciality: geriatric medicine 67 (7.2) 123 (6.8) 1.22 (0.84, 1.77) 1.20 (0.79, 1.82) 1.20 (0.79, 1.83) 
Admission speciality: surgery 298 (32.0) 547(30.2) 1.06 (0.87, 1.30) 1.14 (0.90, 1.44) 1.15 (0.91, 1.45) 
Admission speciality: otherc 98 (10.5) 219 (12.1) 0.85 (0.62, 1.15) 0.86 (0.61, 1.2) 0.86 (0.61, 1.21) 
Any hospital admission in previous year, No 517 (55.6) 1103 (60.9) 1 1 1 
Any hospital admission in previous year, Yes 413 (44.4) 707 (39.1) 1.26 (1.06, 1.49) 1.30 (1.04, 1.62) 1.28 (1.03, 1.60) 
Number items dispensed in previous yeard 65.5 (31-114.8) 51 (27.3-86) 1.01 (1.01, 1.01) 1.01 (1.01, 1.02) 1.01 (1.01, 1.02) 
Number different items dispensed in previous yeard 12 (8-18) 12 (8-17) 1.01 (0.9993, 1.02) 0.92 (0.90, 0.94) 0.91 (0.89, 0.93) 
Length of inpatient stay before the date of CDId 17 (8-34) 14 (6-30) 1.11 (1.08, 1.14) 1.11 (1.08, 1.15) 1.12 (1.08, 1.15) 
Care home residence, No 752 (80.9) 1381 (76.3) 1 1 1 
Care home residence, Yes 178 (19.1) 429 (23.7) 0.75 (0.59, 0.94) 0.65 (0.50, 0.83) 0.65 (0.50, 0.84) 
PPI exposure, No 516 (55.5) 1032 (57.0) 1 1 1 
PPI exposure, Yes 414 (44.5) 778 (43.0) 1.09 (0.91, 1.29) 0.94 (0.76, 1.16) 0.95 (0.77, 1.18) 
H2 exposure, No 871 (93.7) 1707 (94.3) 1 1 1 
H2 exposure, Yes 59 (6.3) 103 (5.7) 1.20 (0.85, 1.70) 1.00 (0.67, 1.49) 1.01 (0.68, 1.51) 
aIQR means inter quartile range. bCharlson score is unknown means that the patient has not been admitted to hospital in the 5 years before the current admission date. cother include: Acute medicine, Cardiology, 9 
Infectious disease, Dermatology, Gastroenterology, Renal medicine, Neurology, Respiratory medicine, Rheumatology, Accident and emergency, Ear nose and throat, Ophthalmology, Urology, GP other than 10 
obstetrics. dOdds ratio for continuous variables are for every unit increase. 11 
Table II:  Subset analysis for those hospitalised less than one week - multivariate odds ratios 12 
of prior 4C exposure and potential confounding variables for HA-CDI vs. controls (221 cases 13 
and 559 controls).  14 
 15 
  Adjusted 4C 
  OR (95% CI) 
Exposed to antibiotics in the previous 6 months, No 1 
Exposed to 4C in the previous 6 months 2.43 (0.998, 5.94) 
Exposed to non-4C in the previous 6 months, Yes 1.11 (0.61, 1.99) 
SIMD 1: most deprived 1 
SIMD 2 1.28 (0.64, 2.56) 
SIMD 3 0.97 (0.47, 2.00) 
SIMD 4 1.54 (0.67, 3.52) 
SIMD 5: least deprived 0.97 (0.41, 2.31) 
Charlson score 0 1 
Charlson score 1 1.09 (0.49, 2.45) 
Charlson score 2 0.80 (0.35, 1.08) 
Charlson score 3 1.88 (0.51, 6.89) 
Charlson score 4+ 9.47 (1.89, 47.56) 
Charlson score Unknown 0.47 (0.23, 0.99) 
Admission speciality: general medicine 1 
Admission speciality: geriatric medicine 1.56 (0.45, 5.43) 
Admission speciality: surgery 0.33 (0.14, 0.80) 
Admission speciality: other 0.65 (0.35, 1.21) 
Any hospital admission in previous year, No 1 
Any hospital admission in previous year, Yes 1.21 (0.72, 2.06) 
Number items dispensed in previous year 1.01 (1.01, 1.02) 
Number different items dispensed in previous year 0.92 (0.86, 0.98) 
Length of inpatient stay before the date of CDI 1.73 (1.49, 2.00) 
Care home residence, No 1 
Care home residence, Yes 1.11 (0.57, 2.19) 
PPI exposure, No 1 
PPI exposure, Yes 1.03 (0.62, 1.73) 
H2 exposure, No 1 
H2 exposure, Yes 0.98 (0.41, 2.33) 
16 
Table III:  The effect of cumulative exposure in a six month period on the adjusted odds of 17 
HA-CDI.  18 
 19 
Cumulative 
antimicrobial 
exposure 
Cases (n=930) 
N (%) 
Controls (n=1810) 
N (%) 
Adjusteda 
OR (95% CI) 
Global P value 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.0006b 
1-7 DDDs 96 (10.3) 213 (11.8) 1.31 (0.95, 1.79)  
8-14 DDDs 100 (10.8) 208 (11.5) 1.40 (1.03, 1.92)  
15-28 DDDs 80 (8.6) 163 (9.0) 1.21 (0.85, 1.72)  
29+ DDDs 120 (12.9) 132 (7.3) 1.90 (1.31, 2.74)  
NAc 0 1 
 
 
Cumulative 4C 
exposure 
 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.006d 
1-7 DDDs 48 (5.2) 89 (4.9) 1.76 (1.14, 2.73)  
8-14 DDDs 29 (3.1) 41 (2.3) 2.16 (1.19, 3.91)  
15-28 DDDs 21 (2.3) 26 (1.4) 1.94 (0.93, 4.03)  
29+ DDDs 23 (2.5) 16 (0.9) 1.63 (0.69, 3.84)  
Only non-4C 275 (29.6) 545 (30.1) 1.29 (1.02, 1.63)  
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), total 20 
number of prescriptions in the previous year, total number of different prescriptions, days since the index admission until CDI, care home 21 
residence,   PPI H2 exposure. bLinear p value (trend test). cTo calculate DDD exposure both quantity and a scaling factor representing the 22 
recommended daily dose are required.  For one observations either or both of these were missing for the antimicrobial exposure variable.  23 
The observation are excluded from the analysis. dglobal p value, not trend test p value (trend test was not possible as “Only non-4C” 24 
making the  levels not ordered).25 
Table IV:  Distribution of temporal antimicrobial exposure and the adjusted odds of HA-CDI.  26 
 27 
Most recent 
exposure in 
previous 6 months 
(any antimicrobial) 
Cases (n=930) 
N (%) 
Controls (n=1810) 
N (%) 
Adjusteda 
OR (95% CI) 
Global P value 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.5b 
<=30 days 94 (10.1) 120 (6.6) 2.17  (1.53, 3.07)  
31-90 days 126 (13.5) 191 (10.6) 1.75 (1.27, 2.41)  
91+ days 176 (18.9) 406 (22.4) 0.97  (0.74, 1.28)  
Most recent 
exposure in 
previous 6 months 
(4C) 
 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.003c 
<=30 days 45 (4.8) 51 2.8) 2.24 (1.32, 3.78)  
31-90 days 39 (4.2) 44 (2.4) 2.47 (1.42, 4.32)  
91+ days 37 (4.0) 77 (4.3) 1.27 (0.76, 2.12)  
Only non-4C 275 (29.6) 545 (30.1) 1.29 (1.02, 1.63)  
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), total 28 
number of prescriptions in the previous year, total number of different prescriptions, days since the index admission until CDI, care home 29 
residence,   PPI H2 exposure. bLinear p value (trend test). cglobal p value, not trend test p value (trend test was not possible as “Only non-30 
4C” making the levels not ordered). 31 
Table V: Adjusted odds of HA-CDI associated with community prescribing of antimicrobials 32 
(Baseline) and assessment of the potential unmeasured confounder.  33 
 34 
hospital 
prescribing 
ratio: P0/P1b 
Any antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
33/33 
(baseline) 
1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 
31/35 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.32 (1.07, 1.64) 1.30 (1.05, 1.62) 
29/37 1.38 (1.11, 1.71) 1.35 (1.09, 1.68) 1.33 (1.07, 1.65) 1.25 (1.00, 1.55) 1.21 (0.97, 1.50) 
27/39 1.36 (1.10, 1.69) 1.32 (1.07, 1.64) 1.29 (1.04, 1.61) 1.17 (0.95, 1.46) 1.12 (0.90, 1.39) 
25/41 1.35 (1.08, 1.67) 1.30 (1.05, 1.61) 1.26 (1.01, 1.56) 1.10 (0.89, 1.37) 1.04 (0.84, 1.29) 
23/43 1.33 (1.07, 1.65) 1.27 (1.02, 1.58) 1.22 (0.99, 1.52) 1.04 (0.84, 1.29) 0.96 (0.77, 1.19) 
21/45 1.32 (1.06, 1.64) 1.25 (1.00, 1.55) 1.19 (0.96, 1.48) 0.98 (0.79, 1.21) 0.89 (0.71, 1.10) 
19/47 1.30 (1.05, 1.62) 1.22 (0.98, 1.52) 1.16 (0.93, 1.44) 0.92 (0.74, 1.14) 0.82 (0.66, 1.02) 
 
4C 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
33/33 
(baseline) 
1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 
31/35 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.75 (1.25, 2.44) 1.72 (1.23, 2.41) 
29/37 1.82 (1.30, 2.54) 1.78 (1.27, 2.49) 1.75 (1.25, 2.45) 1.64 (1.18, 2.30) 1.59 (1.14, 2.23) 
27/39 1.80 (1.28, 2.51) 1.75 (1.25, 2.44) 1.71 (1.22, 2.39) 1.55 (1.11, 2.16) 1.48 (1.06, 2.07) 
25/41 1.78 (1.27, 2.48) 1.71 (1.22, 2.39) 1.66 (1.19, 2.32) 1.46 (1.04, 2.04) 1.37 (0.98, 1.91) 
23/43 1.76 (1.26, 2.46) 1.68 (1.20, 2.35) 1.61 (1.15, 2.26) 1.37 (0.98, 1.91) 1.27 (0.91, 1.77) 
21/45 1.74 (1.24, 2.43) 1.64 (1.18, 2.30) 1.57 (1.12, 2.20) 1.29 (0.92, 1.80) 1.17 (0.84, 1.64) 
19/47 1.72 (1.23, 2.40) 1.61 (1.15, 2.25) 1.53 (1.09, 2.13) 1.21 (0.86, 1.69) 1.08 (0.77, 1.51) 
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), number of 35 
prescriptions in the previous year, number of different prescriptions in the previous year, days since the index admission until CDI, care 36 
home residence (y/n), PPI exposure (y/n) and H2 exposure (y/n) in the previous 6 months and unmeasured hospital prescribing. bP0: the 37 
prevalence of hospital antimicrobial prescribing in those who had not been given antimicrobials in the community; P1: the prevalence of 38 
hospital antimicrobial prescribing in those who have been prescribed antimicrobials in the community. cOR: assumed OR of hospital 39 
prescribing. 40 
Table A1: Sensitivity analysis - adjusted odds of HA-CDI associated with community prescribing of antimicrobials (Baseline) and assessment 41 
of the potential unmeasured confounder with different assumption of hospital antimicrobial prescribing rate (25%, 50%, 75%).  42 
 43 
Overall hospital 
prescribing rate 
hospital 
prescribing 
ratio: P0/P1b 
Difference 
between P0 
and P1 
Any antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
 baselined 0 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 
33% 31/35 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.32 (1.07, 1.64) 1.30 (1.05, 1.62) 
25% 23/27 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.31 (1.06, 1.63) 1.29 (1.04, 1.60) 
50% 48/52 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.11, 1.70) 1.34 (1.08, 1.66) 1.33 (1.07, 1.65) 
75% 73/77 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.72) 1.38 (1.11, 1.71) 1.36 (1.09, 1.68) 1.35 (1.09, 1.67) 
33% 25/41 14 1.35 (1.08, 1.67) 1.30 (1.05, 1.61) 1.26 (1.01, 1.56) 1.10 (0.89, 1.37) 1.04 (0.84, 1.29) 
25% 17/33 14 1.35 (1.08, 1.67) 1.29 (1.04, 1.61) 1.25 (1.01, 1.55) 1.07 (0.86, 1.32) 0.98 (0.79, 1.22) 
50% 42/58 14 1.35 (1.09, 1.67) 1.31 (1.05, 1.62) 1.27 (1.03, 1.58) 1.16 (0.93, 1.44) 1.12 (0.90, 1.39) 
75% 67/83 14 1.35 (1.09, 1.68) 1.32 (1.06, 1.63) 1.29 (1.04, 1.60) 1.21 (0.98, 1.51) 1.19 (0.96, 1.47) 
33% 19/47 28 1.30 (1.05, 1.62) 1.22 (0.98, 1.52) 1.16 (0.93, 1.44) 0.92 (0.74, 1.14) 0.82 (0.66, 1.02) 
25% 11/39 28 1.30 (1.05, 1.61) 1.22 (0.98, 1.51) 1.14 (0.92, 1.42) 0.86 (0.69, 1.07) 0.74 (0.60, 0.92) 
50% 36/64 28 1.31 (1.05, 1.62) 1.24 (1.00, 1.53) 1.18 (0.95, 1.47) 1.00 (0.81, 1.24) 0.94 (0.76, 1.16) 
75% 61/89 28 1.31 (1.06, 1.63) 1.25 (1.01, 1.55) 1.21 (0.97, 1.50) 1.08 (0.87, 1.35) 1.05 (0.84, 1.30) 
Overall hospital 
prescribing rate 
hospital 
prescribing 
ratio: P0/P1b 
Difference 
between P0 
and P1 
4C antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
 baselined 0 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 
33% 31/35 4 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.75 (1.25, 2.44) 1.72 (1.23, 2.41) 
25% 23/27 4 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.73 (1.24, 2.42) 1.70 (1.21, 2.37) 
50% 48/52 4 1.84 (1.31, 2.57) 1.82 (1.30, 2.55) 1.81 (1.29, 2.53) 1.77 (1.26, 2.47) 1.75 (1.25, 2.45) 
75% 73/77 4 1.84 (1.31, 2.57) 1.82 (1.30, 2.55) 1.82 (1.30, 2.54) 1.79 (1.28, 2.50) 1.78 (1.27, 2.49) 
33% 25/41 14 1.78 (1.27, 2.48) 1.71 (1.22, 2.39) 1.66 (1.19, 2.32) 1.46 (1.04, 2.04) 1.37 (0.98, 1.91) 
25% 17/33 14 1.77 (1.27, 2.48) 1.71 (1.22, 2.39) 1.65 (1.18, 2.31) 1.41 (1.01, 1.97) 1.30 (0.93, 1.81) 
50% 42/58 14 1.78 (1.27, 2.49) 1.72 (1.23, 2.41) 1.68 (1.20, 2.35) 1.53 (1.09, 2.14) 1.47 (1.05, 2.06) 
75% 67/83 14 1.78 (1.28, 2.49) 1.74 (1.24, 2.43) 1.70 (1.22, 2.38) 1.60 (1.14, 2.24) 1.57 (1.12, 2.19) 
33% 19/47 28 1.72 (1.23, 2.40) 1.61 (1.15, 2.25) 1.53 (1.09, 2.13) 1.21 (0.86, 1.69) 1.08 (0.77, 1.51) 
25% 11/39 28 1.72 (1.23, 2.40) 1.60 (1.15, 2.24) 1.51 (1.08, 2.11) 1.14 (0.81, 1.59) 0.97 (0.70, 1.36) 
50% 36/64 28 1.72 (1.23, 2.41) 1.63 (1.17, 2.28) 1.56 (1.11, 2.18) 1.32 (0.95, 1.85) 1.24 (0.88, 1.73) 
75% 61/89 28 1.73 (1.24, 2.42) 1.65 (1.18, 2.31) 1.60 (1.14, 2.23) 1.43 (1.02, 2.00) 1.38 (0.99, 1.93) 
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), number of prescriptions in the previous year, number of different prescriptions in the 44 
previous year, days since the index admission until CDI, care home residence (y/n), PPI exposure (y/n) and H2 exposure (y/n) in the previous 6 months and unmeasured hospital prescribing. bP0: the prevalence of 45 
hospital antimicrobial prescribing in those who had not been given antimicrobials in the community; P1: the prevalence of hospital antimicrobial prescribing in those who have been prescribed antimicrobials in the 46 
community. cOR: assumed OR of hospital prescribing. dbaseline OR are the same for different overall hospital antimicrobial prescribing rate (33%, 25%, 50%, 75%) as long as P0=P1. 47 
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